Industry News

Join WhatsApp Channel

- Read more about Aurobindo Pharma gets USFDA nod to market generic Osteoporosis drug
Aurobindo Pharma said it has received final approval from USFDA to manufacture and market generic version of Risedronate Sodium tablets, used in the treatment of Osteoporosis, in the American market.
- Read more about AbbVie Launches Good Morning Hypothyroidism to Help Hypothyroid Patients Manage their Life-Long Condition through Education and a Sense of Community
AbbVie, is introducing Good Morning Hypothyroidism (GMH), an all-inclusive program that focuses on a daily routine for managing the life-long condition of hypothyroidism. When and how patients take their medication can affect the way the body absorbs it so resources encouraging patients to establish and follow to their a daily routine are important. The goal of the new website is to help patients better manage their hypothyroidism by establishing a daily routine, spirit of connection, and a sense of community through tools and resources such as a patient journal, medication refill reminder and a network of hypothyroidism patients.
- Read more about Pfizer reported top-line results of a Phase 3 study of LYRICA Capsules CV in adults with chronic post-traumatic peripheral neuropathic pain
Pfizer Inc. announced top-line results of a Phase 3 study evaluating the efficacy and safety of LYRICA (pregabalin) Capsules CV in adults with chronic post-traumatic peripheral neuropathic pain. The study did not meet its primary efficacy endpoint.
- Read more about Lung cancer experts call for improved EGFR mutation testing to allow all eligible NSCLC patients access to personalised treatment
Insights from experts working on-the-ground in lung cancer, compiled by Boehringer Ingelheim, shed light on challenges faced by patients with advanced stage adenocarcinoma, a type of non-small cell lung cancer (NSCLC), in being tested for EGFR mutations, leaving some without access to the most appropriate treatment for them.
- Read more about FDA grant approval of Empliciti, a new immune-stimulating therapy to treat multiple myeloma
U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.

[adsense:336x280:8701650588]
- Read more about Praxbind (idarucizumab) approved in European Union for the specific reversal of Pradaxa (dabigatran etexilate)
The European Commission has approved Boehringer Ingelheim's Praxbind (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa (dabigatran etexilate) in cases of emergency surgery /urgent procedures or in situations of life-threatening or uncontrolled bleeding. Idarucizumab is the first specific reversal agent for a non-vitamin K antagonist oral anticoagulant (NOAC) to be approved in the European Union.
- Read more about Mylan Launches Generic FazaClo® Orally Disintegrating Tablets
Mylan N.V. announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is used for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment.
- Read more about GSK announces start of phase III study of sirukumab in Giant Cell Arteritis
GSK announced that dosing has commenced in a phase III study evaluating sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody, for the treatment of patients with giant cell arteritis (GCA).
- Read more about Cipla infringing Roche's patent in lung cancer drug: HC
In a setback to Cipla, the Delhi High Court on Friday held that the Indian drug major was infringing Swiss pharmaceutical company Hoffman-La Roche's patent in lung cancer drug erlotinib hydrochloride, sold under the name of Tarceva.
- Read more about U.S. FDA Approves Takeda's NINLARO® (ixazomib), the First and Only Oral Proteasome Inhibitor to Treat Multiple Myeloma
Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) has approved NINLARO® (ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a once-weekly pill.